Recent Developments in Contrast Media

Over the past decade, several clinical studies have shown gadolinium-based magnetic resonance imaging (MRI) contrast agents accumulate in tissues inside patients. This has raised concern because prolonged, elevated levels of gadolinium in the body may cause a nephrogenic systemic fibrosis in patients with severe kidney disease. Adding to this concern were three studies in 2015, which raised new gadolinium safety concerns after it was found the agent also accumulates in the brain

Switch to MR Angiography for PE Mitigated Impact of Recent Contrast Shortage

Imaging Technology News - Magnetic Resonance Imaging (MRI)

Global Contrast Media Shortage Means Urgent Changes in Interventional Radiology Practices

Fluorinated contrast agents for magnetic resonance imaging; a review of recent developments - RSC Advances (RSC Publishing)

Cardiac MRI Contrast Agents Carry Low Risk of Adverse Events

American College of Radiology Classifies VUEWAY as a Group II Agent Relative to NSF

Recent development of contrast agents for magnetic resonance and multimodal imaging of glioblastoma, Journal of Nanobiotechnology

ISMRM: MPI shows promise for visualizing neuroinflammation

American College of Radiology Classifies VUEWAY as a Group II Agent Relative to NSF